Answers are grounded in this paper and cite their sources.
Research over the past decade has demonstrated that atherothrombosis—like rheumatoid arthritis (RA)—is fundamentally a disorder of innate and adaptive immunity (1). Much more than a simple process of lipid incrustation, atherosclerosis is now understood from its earliest stages of foam cell deposition to its late stages of plaque rupture and vessel occlusion to be influenced by a host of systemic inflammatory responses. For the cardiovascular community, this recognition represents a major paradigm shift in thinking about strategies to prevent and treat myocardial infarction and stroke, the 2 vascular disorders that result in more than 50% of all deaths in the US. At the same time, epidemiologic research in the arthritis community has consistently found that RA patients are at increased risk of cardiovascular disease and that this risk is not easily explained by an excess of traditional risk markers for vascular disease or by exceptional elevations of cholesterol (2, 3). As but one example, when compared with healthy women participating in the Nurses' Health Study, women with RA had a 2-fold increase in myocardial infarction after adjustment for usual risk factors (4). It is likely that the excess risk of vascular disease in RA results in part from a systemic inflammatory process leading to disease expression not only in the joints, but also at the level of the vascular endothelium. Perhaps as a result of increased circulating levels of interleukin-6 (IL-6), tumor necrosis factor α (TNFα), and C-reactive protein (CRP), RA patients share elements of endothelial dysfunction that are commonly observed in other patient groups known to develop premature atherothrombosis (5, 6). Almost a decade ago investigators in our group demonstrated that in apparently healthy populations, elevations of IL-6 were predictive of future vascular events (7), and subsequent work has shown increased IL-6 levels to track with arterial stiffness and subclinical atherosclerosis and to inhibit endothelium-dependent vasodilation (8, 9). Prevention of cardiovascular events among high-risk individuals can safely be accomplished with the use of hydroxymethylglutaryl-coenzyme A reductase inhibitors, or “statins,” and treatment guidelines in the US and Europe currently recommend statin therapy for individuals with known atherosclerotic disorders, diabetes, or overt hyperlipidemia (10). However, in addition to being potent inhibitors of cholesterol synthesis, statins reduce inflammatory cell adhesion and monocyte recruitment to endothelial cells, alter smooth muscle migration in developing plaques, favorably affect matrix metalloproteinases, leading to plaque stabilization, and reduce IL-6–induced CRP production in human hepatocytes (11, 12). All of these effects suggest direct antiinflammatory effects of statin therapy. This hypothesis is further supported by the findings of the TARA (Trial of Atorvastatin in Rheumatoid Arthritis) trial, in which 116 subjects with RA were randomly assigned to receive atorvastatin or placebo. The atorvastatin arm experienced a significant reduction in CRP as well as in tender and swollen joint counts (13). Until recently, no prospective primary prevention data were available addressing the potential role of statin therapy among individuals at risk for vascular disease due to an enhanced immune response rather than due to the presence of overt hyperlipidemia. Recognizing that inflammation is a major component of atherosclerosis—and that half of all heart attacks, strokes, and cardiovascular deaths occur among apparently healthy individuals with low-density lipoprotein (LDL) cholesterol levels below current thresholds for therapy—the JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) trial was designed to specifically address whether rosuvastatin 20 mg daily as compared with placebo would prevent vascular events among individuals with low levels of LDL cholesterol (<130 mg/dl) who were nonetheless at elevated risk of vascular disease on the basis of an enhanced innate immune response as determined by a high-sensitivity CRP (hsCRP) level >2 mg/liter (14). As recently reported, the JUPITER trial was stopped early at the recommendation of its Independent Data Monitoring Board following a 44% reduction in the primary end point of major vascular events (P < 0.00001), a 54% reduction in myocardial infarction (P = 0.0002), a 48% reduction in stroke (P = 0.002), a 46% reduction in need for arterial revascularization (P < 0.0001), and a 20% reduction in all-cause mortality (P = 0.02) (14) (Figure 1). All prespecified subgroups within the JUPITER trial benefited significantly from rosuvastatin, including those traditionally considered to be at “low risk” such as women, those with body mass indices less than 25 kg/m2, nonsmokers, and those with Framingham Risk Scores <10% (15). Absolute as well as relative risk reductions were substantial; the 5-year number needed to treat in the JUPITER trial for myocardial infarction, stroke, or death from any cause was 32, a value that is smaller than the 5-year number needed to treat of 50 for statin therapy in primary prevention among men with hyperlipidemia, such as those evaluated in the AFCAPS/TexCAPS (Air Force/Texas Coronary Atherosclerosis Prevention Study) and WOSCOPS (West of Scotland Coronary Prevention Study) trials (16, 17). Thus, the JUPITER trial demonstrates that the strategy of screening for elevated hsCRP followed by aggressive statin therapy is at least as cost-effective as current strategies based solely on LDL cholesterol. Cumulative incidence of cardiovascular events in the JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) trial, according to study group. Top left, Cumulative incidence of the primary end point (nonfatal myocardial infarction, nonfatal stroke, arterial revascularization, hospitalization for unstable angina, or confirmed death from a cardiovascular cause). Top right, Cumulative incidence of nonfatal myocardial infarction, nonfatal stroke, or confirmed death from a cardiovascular cause. Bottom left, Cumulative incidence of arterial revascularization or hospitalization for unstable angina. Bottom right, Cumulative incidence of death from any cause. HR = hazard ratio; 95% CI = 95% confidence interval. Adapted, with permission, from ref. 14. Copyright © 2008 Massachusetts Medical Society. All rights reserved. The success of the JUPITER trial likely reflects the fact that it prospectively targeted inflammation as the core determinant of risk. The JUPITER trial results, however, are entirely consistent with prior data indicating that statin therapy reduces hsCRP in a manner largely independent of LDL cholesterol reduction (18, 19), and that among individuals with stable conditions (20, 21) as well as among those with acute coronary syndromes (22, 23), the observed benefit of statin therapy relates in part to reductions in hsCRP. It is important to recognize that JUPITER was a direct hypothesis testing trial; as reported in 2001 in a post hoc analysis of the AFCAPS/TexCAPS trial, statin use among those with low LDL cholesterol and elevated hsCRP had already been shown to reduce vascular event rates, whereas statin use among those with low LDL cholesterol and low hsCRP resulted in no clinical benefit, despite similar levels of LDL cholesterol reduction (20). The JUPITER trial also prospectively affirms observations made in the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy—Thrombolysis in Myocardial Infarction 22) trial (22) and in the A-to-Z (Aggrastat-to-Zocor) trial (23) that achieving the “dual targets” of LDL cholesterol reduction and hsCRP reduction are both important for maximizing the clinical utility of statin therapy. Patients with systemic inflammatory conditions including RA, systemic lupus erythematosus, and inflammatory bowel disease were excluded from the JUPITER trial, as were patients taking immunosuppressant agents such as cyclosporine, tacrolimus, azathioprine, or long-term glucocorticoids. Thus, direct evidence from the JUPITER trial is not available for RA patients. However, it is well documented that in addition to patients with RA, virtually all patient groups with enhanced systemic inflammation have increased risk of cardiovascular disease regardless of the cause of inflammation, an observation that extends to psoriasis (24) and periodontal disease (25). Thus, it is not unreasonable to consider the presence of RA or another major inflammatory condition as an additional risk marker for cardiovascular disease, particularly if the hsCRP level is >3 mg/liter. The magnitude of risk associated with most chronic inflammatory conditions is less than that of diabetes or smoking, but close to that of moderate hyperlipidemia or hypertension. As such, the presence of RA alone is unlikely to comprise a “coronary heart disease risk equivalent” that will mandate statin therapy. However, because of their increased relative risk, all patients with RA regardless of age or sex should undergo evaluation for total cholesterol, LDL cholesterol, high-density lipoprotein (HDL) cholesterol, and perhaps hsCRP. The Reynolds Risk Scores, which incorporate data on inflammation and genetics as well as traditional risk factors for cardiovascular disease to better compute global risk for cardiovascular disease, can be useful in this setting (26, 27). The Reynolds Risk Scores are freely available at www.reynoldsriskscore.org. Given the results of the JUPITER trial, it may be difficult to successfully complete a large-scale statin trial among those with RA, and thus whether or not individual patients with RA should be treated with a statin requires consideration of probable benefits, risks, and cost. One subgroup within the JUPITER trial is particularly informative for individuals with underlying inflammation as their predominant risk factor. The JUPITER investigators prespecified an analysis of those study participants who had an elevated hsCRP but no other major risk factor for cardiovascular disease. In this subgroup of 6,375 individuals with elevated hsCRP who did not smoke, had no evidence of hypertension or diabetes, and had a low LDL cholesterol and a protective HDL cholesterol, the absolute rate for the trial primary end point remained high in the placebo group, and a risk reduction consistent with the overall trial effect was observed among those allocated to rosuvastatin (hazard ratio 0.63 [95% confidence interval 0.44–0.92], P = 0.01). Future trials will address whether targeted antiinflammatory therapies might have a role in preventing atherosclerotic occlusive vascular events. Currently available inhibitors of both TNFα and IL-6 appear to increase lipid levels (28, 29) and may carry other systemic toxicities, making use of these agents among non-RA patients difficult to justify. Whether or not CRP itself is more than a marker of risk and should be considered as a target for therapy is controversial; the ongoing development of direct CRP inhibitors will make it possible to test this hypothesis directly (30). An alternative approach that our group has suggested is to test the inflammation hypothesis of atherosclerosis using very low-dose methotrexate (MTX) (10 mg weekly). As proposed in the CIRT (Cardiovascular Inflammation Reduction Trial), very low-dose MTX would be compared with placebo among post–myocardial infarction patients and those with stable atherosclerotic disease who are already receiving aggressive vascular care including aspirin, statins, beta-blockers, and inhibitors of the angiotensin-converting enzyme system, but who remain at risk due to persistently elevated levels of hsCRP (31). Given the safety profile and proven antiinflammatory efficacy of very low-dose MTX established in the arthritis community, this approach could provide direct evidence as to whether or not inhibition of inflammation reduces vascular event rates using an agent that does not have concomitant beneficial effects on lipids (such as a statin) or platelet function (such as aspirin). In support of this trial concept, investigators in nonrandomized observational studies report reductions in vascular events and cardiovascular deaths among RA patients being treated with weekly MTX in doses ranging from 10 mg to 20 mg (32). Any decision to use statin therapy among RA patients must be considered as an adjunct—not a substitute—for lifestyle interventions. All RA patients should be provided core information on the clear vascular benefits that accompany weight loss, dietary discretion, smoking cessation, and increased daily exercise. What the JUPITER trial demonstrates, however, is that even with such lifestyle interventions, vascular event rates remain high among apparently healthy men and women with elevated hsCRP even if lipid levels are low, and that the use of statin therapy in this population yields large clinical benefits including reductions in disabling stroke as well as in all-cause mortality. It is thus not surprising that many within the arthritis community have raised the hypothesis that the JUPITER trial data might well be generalized to the RA patient.
No takes yet. Share an insight, caveat, or question.
Ridker et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: